abstract |
The present application relates to methods of treatment with anti-ErbB receptor antibody-maytansinoid conjugates, and products suitable for use in such methods. In particular, the present invention relates to ErbB receptor directed cancer therapy using anti-ErbB receptor antibody-maytansinoid conjugates. |